Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Nov;96(11):810-5.
doi: 10.1111/j.1349-7006.2005.00106.x.

Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma

Chie Nishioka  1 , Shigeki Takemoto, Sayo Kataoka, Shigeo Yamanaka, Toshiaki Moriki, Momoko Shoda, Toshiki Watanabe, Hirokuni Taguchi
Affiliations

Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma

Chie Nishioka et al. Cancer Sci. 2005 Nov.

Abstract

Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive disease with poor prognosis. CD30(+) cells are frequently observed in lymph node cells and peripheral blood mononuclear cells of ATL patients. In order to elicit the role of CD30(+) cells in ATL development, we investigated expression of the membrane type of CD30 (mCD30) and the soluble form of CD30 (sCD30) on ATL cells. Both mCD30 and sCD30 are expressed on various numbers of ATL cells in vivo as well as cell lines such as MT-2, L540 and Karpas 299. The level of serum sCD30 in each clinical stage showed an elevated level in patients with acute type (mean +/- standard error; 545.2 +/- 18.6 U/mL) rather than with lymphoma type ATL (327.62 +/- 94.85 U/mL). In four patients whose sera were stored and examined longitudinally, the levels decreased following the response to chemotherapy but not in patients with chemotherapy resistance. Thus, our results imply that sCD30 levels may be another useful marker for the activity and aggressiveness of ATL.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CD30 expressing in cell lines. Flow cytometric analysis with anti‐CD4 and anti‐CD30 antibodies and enzyme‐linked immunosorbent assay of culture supernatant were performed using CD30 expressing cell lines. All cell lines express both mCD30 (a) and sCD30 (b). L‐540, Hodgkin and Reed‐Sternberg cell line; Karpas 299, anaplastic large cell lymphoma cell line; MT‐2, human T‐cell leukemia virus type 1‐infected cell line.
Figure 2
Figure 2
sCD30 levels in sera of adult T‐cell leukemia/lymphoma (ATL) patients. Serum levels of sCD30 were plotted in patients with ATL and B cell malignancy, human T‐cell leukemia virus type 1 carriers and healthy donors. The pre‐ and post‐treatment sCD30 concentrations in patients with ATL were correlated with the clinical stage of disease. In patients 5 and 6, serum sCD30 levels of pre‐ and post‐treated states are connected by a solid line. The terms were 93 days in patient 5 and 100 days in patient 6. In patients 7 and 10, the levels after and before relapse are also lined. The terms were 134 days in patient 7 and 189 days in patient 10.
Figure 3
Figure 3
The association between serum sCD30 levels and clinical disease progression. Longitudinal monitoring of serum sCD30 concentrations was performed in three patients with acute type and one patient with lymphoma‐type adult T‐cell leukemia/lymphoma (ATL). Serum sCD30(▪),sIL‐2R(•) and lactate dehydrogenase(◊) and the number of ATL cells(▵) in peripheral blood of ATL patients were examined. Arrows indicate the chemotherapy regimens, CHOP‐MMV, CHOP and THP‐COP, respectively. (a) Patient 5 with therapy resistance showed high levels of sCD30 even after chemotherapy. (b) In patient 6, who responded well to therapy, sCD30 decreased following effective chemotherapy. (c) In patient 7, the level of sCD30 elevated before a relapse. After relapse, patient 7, who was resistant to therapy, showed high levels of sCD30. (d) In patient 10, who relapsed with lymphoma‐type ATL, sCD30 increased according to the clinical relapse.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Takatsuki K, Uchiyama T, Sagawa K, Yodoi J. Adult T‐cell leukemia in Japan. In: Seno S, Takaku F, Irino S, eds. Topics in Hematology, Proceedings of the 16th International Congress of Hematology. Amsterdam, The Netherlands: Excerpta Medica, 1977; 73–7.
    1. Uchiyama T, Yodoi J, Segawa K, Takatsuki K, Uchino H. Adult T‐cell leukemia: Clinical and hematologic features of 16 cases. Blood 1977; 50: 481–92. - PubMed
    1. Shimoyama M, Members of The Lymphoma Study Group ( 1984– 87). Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukemia‐lymphoma. Br J Haematol 1991; 79: 428–37. - PubMed
    1. Takemoto S, Matsuoka M, Yamaguchi K, Takatsuki K. A novel diagnostic method of adult T‐cell leukemia: Monoclonal integration of human T‐cell lymphotropic virus type I provirus DNA detected by inverse polymerase chain reaction. Blood 1994; 84: 3080–5. - PubMed
    1. Takemoto S, Mulloy JC, Cereseto A et al. Proliferation of adult T‐cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA 1997; 94: 13897–902. - PMC - PubMed

Publication types